tiprankstipranks
Trending News
More News >
AstraZeneca PLC (SE:AZN)
:AZN
Sweden Market

AstraZeneca (AZN) Stock Forecast & Price Target

Compare
2 Followers
See the Price Targets and Ratings of:

AZN Analyst Ratings

Strong Buy
16Ratings
Strong Buy
13 Buy
2 Hold
1 Sell
Based on 16 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

kr1,786.50
▼(-3.80% Downside)
Based on 16 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is kr1,786.50 with a high forecast of kr2,250.81 and a low forecast of kr20.18. The average price target represents a -3.80% change from the last price of kr1,857.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"kr19","577":"kr577","1135":"kr1,135","1693":"kr1,693","2251":"kr2,251"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2250.8134880000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr2.25K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1786.5045674300002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr1.79K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.183925300000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr20.18</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,577,1135,1693,2251],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1698.393,1740.8868836923077,1783.3807673846154,1825.874651076923,1868.3685347692308,1910.8624184615385,1953.3563021538462,1995.850185846154,2038.3440695384616,2080.8379532307695,2123.331836923077,2165.825720615385,2208.3196043076923,{"y":2250.8134880000002,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1698.393,1705.1708128792309,1711.9486257584615,1718.7264386376924,1725.5042515169232,1732.2820643961538,1739.0598772753847,1745.8376901546155,1752.6155030338464,1759.393315913077,1766.1711287923079,1772.9489416715387,1779.7267545507693,{"y":1786.5045674300002,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1698.393,1569.2999942538463,1440.2069885076924,1311.1139827615384,1182.0209770153847,1052.927971269231,923.834965523077,794.7419597769232,665.6489540307693,536.5559482846156,407.4629425384617,278.3699367923077,149.276931046154,{"y":20.183925300000002,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1517.243,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1594.235,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1444.837,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1374.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1345.566,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1338.686,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1402.082,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1492.527,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1551.911,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1538.055,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1709.28,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1686.021,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1698.393,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Targetkr2,251Average Price Targetkr1,787Lowest Price Targetkr20.18
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
kr1,993.93kr2,152.95
Buy
15.94%
Upside
Reiterated
02/25/26
UBS Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on SE:AZN
Berenberg Bank
Berenberg Bank
kr1,957.09kr2,079.41
Buy
11.98%
Upside
Reiterated
02/18/26
Berenberg Bank Remains a Buy on AstraZeneca (AZN)
Deutsche Bank  Analyst forecast on SE:AZN
Deutsche Bank
Deutsche Bank
kr1,406.66
Sell
-24.25%
Downside
Reiterated
02/16/26
Deutsche Bank Keeps Their Sell Rating on AstraZeneca (AZN)
DZ BANK AG Analyst forecast on SE:AZN
DZ BANK AG
DZ BANK AG
Hold
Reiterated
02/12/26
DZ BANK AG Remains a Hold on AstraZeneca (AZN)
Goldman Sachs Analyst forecast on SE:AZN
Goldman Sachs
Goldman Sachs
kr2,004.81kr2,017.9
Buy
8.66%
Upside
Reiterated
02/11/26
Goldman Sachs Keeps Their Buy Rating on AstraZeneca (AZN)
Citi
kr2,079.41
Buy
11.98%
Upside
Reiterated
02/11/26
AstraZeneca (AZN) Gets a Buy from Citi
Bernstein Analyst forecast on SE:AZN
Bernstein
Bernstein
kr22.51kr2,250.81
Buy
21.21%
Upside
Assigned
02/10/26
AstraZeneca (AZN) Gets a Buy from Bernstein
Bank of America Securities Analyst forecast on SE:AZN
Bank of America Securities
Bank of America Securities
kr2,018.39
Buy
8.69%
Upside
Reiterated
02/10/26
AstraZeneca: Buy Rating Backed by Solid Execution, Attractive Valuation, and Late‑Stage Pipeline Upside
Barclays
kr2,018.25
Buy
8.68%
Upside
Reiterated
02/10/26
Barclays Remains a Buy on AstraZeneca (AZN)
Kepler Capital  Analyst forecast on SE:AZN
Kepler Capital
Kepler Capital
kr1,382.29
Hold
-25.56%
Downside
Reiterated
02/10/26
AstraZeneca (AZN) Receives a Hold from Kepler Capital
J.P. Morgan Analyst forecast on SE:AZN
J.P. Morgan
J.P. Morgan
kr1,957.09
Buy
5.39%
Upside
Reiterated
02/10/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Jefferies
kr1,834.77
Buy
-1.20%
Downside
Reiterated
02/10/26
Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)
Shore Capital Analyst forecast on SE:AZN
Unknown Analyst
Shore Capital
Not Ranked
Shore Capital
Buy
Reiterated
01/16/26
Shore Capital Sticks to Its Buy Rating for AstraZeneca (AZN)
Morgan Stanley Analyst forecast on SE:AZN
Morgan Stanley
Morgan Stanley
kr1,712.58kr1,896.07
Buy
2.10%
Upside
Reiterated
12/03/25
AstraZeneca: Top Pick in a Growing Pharmaceutical Sector with Promising Pipeline and Resolved Overhangs
HSBC Analyst forecast on SE:AZN
Unknown Analyst
HSBC
Not Ranked
HSBC
kr1,319.41kr1,487.04
Buy
-19.92%
Downside
Reiterated
12/02/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
kr1,993.93kr2,152.95
Buy
15.94%
Upside
Reiterated
02/25/26
UBS Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on SE:AZN
Berenberg Bank
Berenberg Bank
kr1,957.09kr2,079.41
Buy
11.98%
Upside
Reiterated
02/18/26
Berenberg Bank Remains a Buy on AstraZeneca (AZN)
Deutsche Bank  Analyst forecast on SE:AZN
Deutsche Bank
Deutsche Bank
kr1,406.66
Sell
-24.25%
Downside
Reiterated
02/16/26
Deutsche Bank Keeps Their Sell Rating on AstraZeneca (AZN)
DZ BANK AG Analyst forecast on SE:AZN
DZ BANK AG
DZ BANK AG
Hold
Reiterated
02/12/26
DZ BANK AG Remains a Hold on AstraZeneca (AZN)
Goldman Sachs Analyst forecast on SE:AZN
Goldman Sachs
Goldman Sachs
kr2,004.81kr2,017.9
Buy
8.66%
Upside
Reiterated
02/11/26
Goldman Sachs Keeps Their Buy Rating on AstraZeneca (AZN)
Citi
kr2,079.41
Buy
11.98%
Upside
Reiterated
02/11/26
AstraZeneca (AZN) Gets a Buy from Citi
Bernstein Analyst forecast on SE:AZN
Bernstein
Bernstein
kr22.51kr2,250.81
Buy
21.21%
Upside
Assigned
02/10/26
AstraZeneca (AZN) Gets a Buy from Bernstein
Bank of America Securities Analyst forecast on SE:AZN
Bank of America Securities
Bank of America Securities
kr2,018.39
Buy
8.69%
Upside
Reiterated
02/10/26
AstraZeneca: Buy Rating Backed by Solid Execution, Attractive Valuation, and Late‑Stage Pipeline Upside
Barclays
kr2,018.25
Buy
8.68%
Upside
Reiterated
02/10/26
Barclays Remains a Buy on AstraZeneca (AZN)
Kepler Capital  Analyst forecast on SE:AZN
Kepler Capital
Kepler Capital
kr1,382.29
Hold
-25.56%
Downside
Reiterated
02/10/26
AstraZeneca (AZN) Receives a Hold from Kepler Capital
J.P. Morgan Analyst forecast on SE:AZN
J.P. Morgan
J.P. Morgan
kr1,957.09
Buy
5.39%
Upside
Reiterated
02/10/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Jefferies
kr1,834.77
Buy
-1.20%
Downside
Reiterated
02/10/26
Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)
Shore Capital Analyst forecast on SE:AZN
Unknown Analyst
Shore Capital
Not Ranked
Shore Capital
Buy
Reiterated
01/16/26
Shore Capital Sticks to Its Buy Rating for AstraZeneca (AZN)
Morgan Stanley Analyst forecast on SE:AZN
Morgan Stanley
Morgan Stanley
kr1,712.58kr1,896.07
Buy
2.10%
Upside
Reiterated
12/03/25
AstraZeneca: Top Pick in a Growing Pharmaceutical Sector with Promising Pipeline and Resolved Overhangs
HSBC Analyst forecast on SE:AZN
Unknown Analyst
HSBC
Not Ranked
HSBC
kr1,319.41kr1,487.04
Buy
-19.92%
Downside
Reiterated
12/02/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months
xxx
Success Rate
15/21 ratings generated profit
71%
Average Return
+4.58%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +4.58% per trade.
1 Year
Success Rate
36/38 ratings generated profit
95%
Average Return
+19.89%
a rating ―
Copying Matthew Weston's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +19.89% per trade.
2 Years
xxx
Success Rate
19/19 ratings generated profit
100%
Average Return
+34.53%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +34.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating
Oct 25
Nov 25
Dec 25
Jan 26
Feb 26
Strong Buy
2
1
0
0
0
Buy
30
36
34
29
29
Hold
7
6
2
1
2
Sell
2
5
6
5
5
Strong Sell
0
0
0
0
0
total
41
48
42
35
36
In the current month, AZN has received 29 Buy Ratings, 2 Hold Ratings, and 5 Sell Ratings. AZN average Analyst price target in the past 3 months is 1,786.50.
Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is kr22.48 with a range of kr21.36 to kr23.97. The previous quarter’s EPS was kr19.11. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.
Next quarter’s earnings estimate for AZN is kr22.48 with a range of kr21.36 to kr23.97. The previous quarter’s EPS was kr19.11. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is kr132.36B with a range of kr129.22B to kr137.92B. The previous quarter’s sales results were kr142.59B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.
Next quarter’s sales forecast for AZN is kr132.36B with a range of kr129.22B to kr137.92B. The previous quarter’s sales results were kr142.59B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Stock Forecast FAQ

What is SE:AZN’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 1,786.50.
    What is SE:AZN’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for SE:AZN, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is AstraZeneca PLC a Buy, Sell or Hold?
        AstraZeneca PLC has a consensus rating of Strong Buy, which is based on 13 buy ratings, 2 hold ratings and 1 sell ratings.
          What is AstraZeneca PLC’s share price target?
          The average share price target for AstraZeneca PLC is 1,786.50. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is kr2,250.81 ,and the lowest forecast is kr20.18. The average share price target represents -3.80% Decrease from the current price of kr1,857.
            What do analysts say about AstraZeneca PLC?
            AstraZeneca PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
              How can I buy shares of AstraZeneca PLC?
              To buy shares of SE:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.